Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy.

about

The Role of Food Antioxidants, Benefits of Functional Foods, and Influence of Feeding Habits on the Health of the Older Person: An Overview.

P2860

Q47161449-F9042F25-692B-40A8-9429-8186C4F94A55

P2860

Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy.

Item

http://www.wikidata.org/entity/Q41667368

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Heterocyclic compounds as key ...... n Alzheimer's disease therapy.

@en

type

Item

label

Heterocyclic compounds as key ...... n Alzheimer's disease therapy.

@en

prefLabel

Heterocyclic compounds as key ...... n Alzheimer's disease therapy.

@en

P1476

Heterocyclic compounds as key ...... in Alzheimer's disease therapy

@en

P2093

Asha Hiremathad

http://www.w3.org/2001/XMLSchema#string

Luca Piemontese

http://www.w3.org/2001/XMLSchema#string

P2860

Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists

On the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

Telmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPARγ and the Akt/GSK-3β pathway.

Rational design of a structural framework with potential use to develop chemical reagents that target and modulate multiple facets of Alzheimer's disease.

Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease.

Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease.

Recent progress in repositioning Alzheimer's disease drugs based on a multitarget strategy.

Heterocyclic Scaffolds for the Treatment of Alzheimer's Disease.

P304

1256-1261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/1673-5374.213541

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Luca Piemontese

Asha Hiremathad

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28966636

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

5607816

http://www.w3.org/2001/XMLSchema#string

Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy.

about

P2860

P2860

Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932